153 related articles for article (PubMed ID: 34030112)
1. Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Orlov SV; Iyevleva AG; Filippova EA; Lozhkina AM; Odintsova SV; Sokolova TN; Mitiushkina NV; Tiurin VI; Preobrazhenskaya EV; Romanko AA; Martianov AS; Ivantsov AO; Aleksakhina SN; Togo AV; Imyanitov EN
Transl Oncol; 2021 Aug; 14(8):101121. PubMed ID: 34030112
[TBL] [Abstract][Full Text] [Related]
2. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
3. LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
Alexander M; Wei J; Parakh S; John T; Kao S; Nagrial A; Bowyer S; Warburton L; Moore M; Hughes BGM; Clay TD; Pavlakis N; Solomon BJ; Itchins M
JTO Clin Res Rep; 2023 Apr; 4(4):100490. PubMed ID: 37077199
[TBL] [Abstract][Full Text] [Related]
4. Real world study of safety and efficacy of lorlatinib as second line and beyond in
Biswas B; Ghadyalpatil NS; Patil S; Patel A; Ganguly S; Rathore A; Guleria B; Tarannum CF; Ghosh J; Kondapally MS; Thippeswamy R; Reddy SHP; Roy S
Ecancermedicalscience; 2024; 18():1667. PubMed ID: 38439810
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
7. Later-Line Treatment with Lorlatinib in
Hochmair MJ; Fabikan H; Illini O; Weinlinger C; Setinek U; Krenbek D; Prosch H; Rauter M; Schumacher M; Wöll E; Wass R; Brehm E; Absenger G; Bundalo T; Errhalt P; Urban M; Valipour A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171712
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
10. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N; Gillis R; Kilickap S; Froesch P; Orlov S; Filippova E; Demirci U; Christopoulos P; Cicin I; Basal FB; Yilmaz C; Fedor M; Korkmaz T; Paydas S; Gautschi O; Zirtiloglu A; Eralp Y; Cinkir HY; Sezer A; Erman M; Tural D; Turna H; Mazieres J; Dudnik E; Reguart N; Camidge DR; Ng TL; Şenler FÇ; Beypınar İ; Yazılıtaş D; Demirkazık A; Karaoğlu A; Okutur K; Coşkun HŞ; Şendur MAN; Isikdogan A; Cabuk D; Yumuk PF; Yıldız I; Kaplan MA; Özyılkan Ö; Öztop İ; Olmez OF; Aydin K; Aydıner A; Meydan N; Grinberg RD; Roisman LC
Lung Cancer; 2020 Oct; 148():48-54. PubMed ID: 32799090
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced
Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS; Ou SI; Mileham KF; Riely GJ
JTO Clin Res Rep; 2023 Aug; 4(8):100546. PubMed ID: 37644967
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
13. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E; Shaw AT; Bearz A; Camidge DR; Solomon BJ; Bauman JR; Bauer TM; Peters S; Toffalorio F; Abbattista A; Thurm H; Peltz G; Wiltshire R; Besse B
Ann Oncol; 2021 May; 32(5):620-630. PubMed ID: 33639216
[TBL] [Abstract][Full Text] [Related]
14. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N; Christopoulos P; Kauffmann-Guerrero D; Stratmann J; Riedel R; Schaefer M; Alt J; Gütz S; Christoph DC; Laack E; Faehling M; Fischer R; Fenchel K; Haen S; Heukamp L; Schulz C; Griesinger F
Ther Adv Med Oncol; 2021; 13():1758835920980558. PubMed ID: 33613692
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Chuang CH; Chen HL; Chang HM; Tsai YC; Wu KL; Chen IH; Chen KC; Lee JY; Chang YC; Chen CL; Tu YK; Hung JY; Yang CJ; Chong IW
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921762
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
17. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
18. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
19. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
20. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Zhu VW; Lin YT; Kim DW; Loong HH; Nagasaka M; To H; Ang YL; Ock CY; Tchekmedyian N; Ou SI; Syn NL; Reungwetwattana T; Lin CC; Soo RA
J Thorac Oncol; 2020 Sep; 15(9):1484-1496. PubMed ID: 32360579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]